We assumed that crizotinib may target RXRα and GATA1, both of which play a role in hematological malignancies, and based on the fact that targeting RXRα and GATA1 may overcome drug resistance, we thus confirmed our estimations based on classifying the mean log10IC50 values of crizotinib in 59 NCI cell lines depending on the cancer type of the cells. The gene discussed is RXRA; the disease is hematologic disorder.